Gene · 79001
VKORC1: vitamin K epoxide reductase complex subunit 1
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. VKORC1: vitamin K epoxide reductase complex subunit 1. Genes, record 79001. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/79001
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| Q9BQB6 | Vitamin K epoxide reductase complex subunit 1 | 163 | 6 | Ensembl, GeneID, HGNC |
Source UniProt
Patents67
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026004568 A | 2026-01-14 | 69695 | Q9BQB6 | Espacenet |
| EP 4650780 A2 | 2025-11-19 | 11219 | Q9BQB6 | Espacenet |
| JP 2025147176 A | 2025-10-06 | 14076 | Q9BQB6 | Espacenet |
| JP 2025529142 A | 2025-09-04 | 5229 | Q9BQB6 | Espacenet |
| JP 2025529142 A | 2025-09-04 | 8030 | Q9BQB6 | Espacenet |
| US 12371689 B2 | 2025-07-29 | 5229 | Q9BQB6 | Espacenet |
| US 12371689 B2 | 2025-07-29 | 8030 | Q9BQB6 | Espacenet |
| JP 2025517970 A | 2025-06-12 | 11219 | Q9BQB6 | Espacenet |
| JP 2025028160 A | 2025-02-28 | 14076 | Q9BQB6 | Espacenet |
| KR 1020250010750 A | 2025-01-21 | 14076 | Q9BQB6 | Espacenet |
1 to 10 of 67
See all 67 patentsDrugs8
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| ACENOCOUMAROL | CHEMBL397420 | Vitamin k epoxide reductase complex subunit 1 isoform 1 inhibitor | INHIBITOR | ChEMBL |
| DICUMAROL | CHEMBL1466 | Vitamin k epoxide reductase complex subunit 1 isoform 1 inhibitor | INHIBITOR | ChEMBL |
| PHENINDIONE | CHEMBL711 | Vitamin k epoxide reductase complex subunit 1 isoform 1 inhibitor | INHIBITOR | ChEMBL |
| PHENPROCOUMON | CHEMBL1465 | Vitamin k epoxide reductase complex subunit 1 isoform 1 inhibitor | INHIBITOR | ChEMBL |
| TECARFARIN | CHEMBL2105664 | Vitamin k epoxide reductase complex subunit 1 isoform 1 inhibitor | INHIBITOR | ChEMBL |
| WARFARIN | CHEMBL1464 | Vitamin k epoxide reductase complex subunit 1 isoform 1 inhibitor | INHIBITOR | ChEMBL |
| WARFARIN POTASSIUM | CHEMBL1200772 | Vitamin k epoxide reductase complex subunit 1 isoform 1 inhibitor | INHIBITOR | ChEMBL |
| WARFARIN SODIUM | CHEMBL1200879 | Vitamin k epoxide reductase complex subunit 1 isoform 1 inhibitor | INHIBITOR | ChEMBL |
Trials134
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT07603700 | WARFARIN | ClinicalTrials.gov | ||
| NCT07456085 | WARFARIN | PHASE3 | ClinicalTrials.gov | |
| NCT07434661 | WARFARIN | PHASE3 | ClinicalTrials.gov | |
| NCT07077954 | WARFARIN | PHASE1 | ClinicalTrials.gov | |
| NCT06884384 | WARFARIN | ClinicalTrials.gov | ||
| NCT06789588 | WARFARIN | PHASE3 | ClinicalTrials.gov | |
| NCT06606275 | WARFARIN | ClinicalTrials.gov | ||
| NCT06322953 | WARFARIN | PHASE3 | ClinicalTrials.gov | |
| NCT06278051 | WARFARIN | ClinicalTrials.gov | ||
| NCT06045858 | WARFARIN | PHASE3 | ClinicalTrials.gov |
1 to 10 of 134
See all 134 trialsNIH grants1,643
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | VKORC1 papers | Newest fiscal year |
|---|---|---|---|
| K24HL133373 | Discovery, Implementation and Mentorship in Personalized Cardiovascular Pharmacotherapy | 18 | 2025 |
| P30CA021765 | Cancer Center Support Grant (CCSG) | 17 | 2025 |
| R01HL121718 | Structural and Functional Basis of the Vitamin K Cycle | 15 | 2025 |
| T15LM007033 | Biomedical Informatics Training Program at Stanford | 13 | 2025 |
| R01GM131008 | NEW CHEMICAL PROBES ENABLE MASS SPECTROMETRY-BASED FOOTPRINTING OF HUMAN PROTEIN STRUCTURE IN LIPID MEMBRANES AND CELLS | 12 | 2025 |
| T32GM007569 | Clinical Pharmacology Training Program | 11 | 2025 |
| U01HG006379 | EHR-based Genomic Discovery and Implementation [Funded Extension] | 11 | 2025 |
| P30ES007033 | University of Washington Interdisciplinary Center for Exposures, Diseases, Genomics & Environment | 8 | 2025 |
| U24HG010615 | PharmGKB | 6 | 2025 |
| U54MD007600 | Center for Collaborative Research in Health Disparities | 6 | 2025 |
1 to 10 of 1,643Source NIH's project files
See all 1,643 nih grantsPapers3,438
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Limitations of VKORC1 rs9934438 as a Surrogate Marker for Vitamin K Antagonist Dose Adjustment. | Basic Clin Pharmacol Toxicol | 2026 | 42823629 | PubTator, text mining | PubMed |
| Machine Learning-Directed Explainable Artificial Intelligence and Bayesian Predictions of Warfarin Therapeutic Dose for Orthopedic Indications. | Curr Pharm Des | 2026 | 42813643 | PubTator, text mining | PubMed |
| Allelic Frequency of Single-Nucleotide Polymorphisms in CYP2C9, VKORC1, and CYP4F2 Genetic Variants in Patients With Mechanical Heart Valves on Acenocoumarol Drug Therapy. | Cureus | 2026 | 42801138 | PubTator, text mining | PubMed |
| Vietnamese pharmacogenomic variation in global context: a systematic review and meta-analysis for clinical implementation. | Front Pharmacol | 2026 | 42756309 | PubTator, text mining | PubMed |
| Clinically Relevant Pharmacogenomic Variant Frequencies in Kazakh, Russian, and Uzbek Population Groups Residing in Kazakhstan. | Biology (Basel) | 2026 | 42737909 | PubTator, text mining | PubMed |
| Prognostic value of genes associated with metastasis and propionate metabolism in rectal cancer. | J Gastrointest Oncol | 2026 | 42703504 | PubTator, text mining | PubMed |
| Cost-Effectiveness of Pharmacogenomics-Guided Treatment in Cardiovascular Disease: An Umbrella Review. | Pharmgenomics Pers Med | 2026 | 42662837 | PubTator, text mining | PubMed |
| γ-glutamyl carboxylase inhibition by Anisindione. | Structure | 2026 | 42660115 | PubTator, text mining | PubMed |
| Warfarin-Induced Developmental Toxicity: Insights into Embryogenesis, Teratogenicity, and Molecular Pathways. | J Dev Biol | 2026 | 42647228 | PubTator, text mining | PubMed |
| Pharmacogenomics in Dentistry: From CYP-Mediated Drug Response to Precision Prescribing in Oral Healthcare. | Oral Dis | 2026 | 42630019 | PubTator, text mining | PubMed |
1 to 10 of 3,438
See all 3,438 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/79001
GET https://conductscience.org/api/genes/v1/79001/patents?page=2